Global Castrate-resistant Prostate Cancer Market

Global Castrate-resistant Prostate Cancer Market size was valued at US$ 14.05 Bn in 2025 and the total revenue is expected to grow at 8.5% through 2026 to 2032, reaching nearly US$24.87Bn.

Global Castrate-resistant Prostate Cancer Market Overview:

To know about the Research Methodology :- Request Free Sample Report

Global Castrate-resistant Prostate Cancer Market Dynamics:

The increased prevalence of castrate-resistant prostate cancer, as well as the increasing acceptance of new medicines and an unhealthy lifestyle, are expected to drive market expansion. The market's growth rate is also fueled by the need for rapid alternative treatments and major companies' expenditures in R&D.

The high frequency of prostate cancer that evolves into castrate-resistant prostate cancer within a few years after diagnosis is causing a rise in the prevalence of castrate-resistant prostate cancer across the world. In the US, over 3.6 million men were diagnosed with prostate cancer in 2025, with a 12.2 % occurrence for metastatic castrate-resistant prostate cancer (mCRPC). The growing trend of early diagnosis of the disease is linked to a better prognosis. Hence, these factors are likely to motivate market expansion. Further, 85.0% of demographics had a favorable response to conventional chemical castration therapy during the first session. Furthermore, the availability of patient-friendly healthcare expenditures like health insurance offered by various firms is probable to enhance the market for castrate-resistant prostate cancer.

Another issue affecting the development of the segments is the lack of a consistent treatment sequence. Treatment options vary greatly based on the patient's features and the physician's inclination. These factors are expected to influence the growth of the castrate-resistant prostate cancer market.

Global Castrate-resistant Prostate Cancer Market Segment Analysis:

The  chemotherapy Therapy segment is anticipated to adhere to the growth of the Castrate-resistant Prostate Cancer Market.

Global Castrate-resistant Prostate Cancer Market Regional Segment:

North America region dominated the market growth in 2025, the key factors attributing to the growth of the market are the high incidence of the conditions, the existence of key market participants, and growing research and development activities. The US is estimated to lead the market growth in North America owing to advantageous reimbursement policies offered by the government. Jevtana, for example, is covered under Medicare Part B coverage. J9043 and C9276 are the codes for it in the Healthcare Common Procedure Coding System. As a result of the aforementioned reasons, the US market is anticipated to be one of the largest and continue to expand in the future.

Further, mergers and collaborations are supporting the growth of the region for instance, in June 2020, Exelixis, Inc., signed a partnership with Roche-Genentech and Takeda, to launch a phase III clinical study in men with metastatic castration-resistant prostate cancer to assess the safety and effectiveness of cabozantinib in combination with atezolizumab (mCRPC). Hence, the factor is likely to create more opportunities for the budding key players to enter the market.

The objective of the report is to present a comprehensive analysis of the Global  Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Global Market dynamics, structure by analyzing the market segments and project the Global Castrate-resistant Prostate Cancer Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Global  Market make the report investor’s guide.

Global Castrate-resistant Prostate Cancer Market Scope: Inquire before buying

Global Castrate-resistant Prostate Cancer Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Global Castrate-resistant Prostate Cancer Market Key Players

1. Johnson & Johnson – (Janssen Pharmaceuticals)
2. Pfizer Inc.
3. Astellas Pharma Inc.
4. Sanofi S.A.
5. Bayer AG
6. Novartis AG
7. AstraZeneca plc
8. Merck & Co., Inc.
9. Bristol-Myers Squibb Company
10. Roche Holding AG
11. Eli Lilly and Company
12. AbbVie Inc.
13. Amgen Inc.
14. Ipsen Group
15. Clovis Oncology
16. Dendreon Pharmaceuticals LLC
17. Endo Pharmaceuticals Inc.
18. Myovant Sciences Ltd.
19. Orion Corporation
20. Tolmar Pharmaceuticals, Inc.
21. GlaxoSmithKline PLC (GSK)
22. Sun Pharmaceutical Industries Ltd